The Pseudovax trial featured on national television
Before the Christmas break, the major Norwegian TV channel TV2 visited the Radium Hospital to learn about the Pseudovax trial. The first patient that recived the vaccine, Mette, was the main focus, together with comments from general secretary Ingrid Stenstadvold Ross in the Norwegian Cancer Society and Kjersti Flatmark, one of the lead investigators of the study.
The Pseudovax clinical trial will evaluate a novel cancer vaccine developed at the Norwegian Radium Hospital specifically for patients with Pseudomyxoma peritonei (PMP) .
“If the vaccine proves to be effective, we hope that this could become an new treatment option for patients with PMP who are not cured by surgery,” Flatmark says.
The vaccine aims to stimulate the patient’s own immune system to recognize and kill cancer cells.
From the initial idea to starting this clinical trial, the development process took five years.
“This is an unusually short timeframe in a medical context, and we are very proud of that,” Flatmark says. At the same time, she emphasizes that the vaccine is still in an early phase. “We cannot promise an effect. The study will run for several years, and only then will we be able to say more about how well it works.”
Photo: Annette Torgunrud
A total of ten patients will be included in the study. So far, Mette is one of two patients who have started treatment. “We are very excited to see how patients respond to this vaccine, and we look forward to following Mette’s progress further” Flatmark says.
Links:
The TV2 article:
Mette (61) er den første i verden: – Jeg føler meg veldig heldig
Read more about the study: The Pseudovax project
The Translational Cancer Therapy Group, led by Kjersti Flatmark